Navigation Links
BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Date:8/22/2007

r cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: BioMarin's products and product candidates, commercialization of BioMarin's products; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the commercialization of BioMarin's products; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medici
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
9. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 Research ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation (the ... has received commitments from two institutional healthcare investors to ... Company,s common stock in an at-the-market registered direct offering ... common stock. The Company entered into a ... the Company agreed to sell an aggregate of 3,000,000 ...
(Date:5/28/2015)... May 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapeutics, primarily in the areas of ... public offering of 26 million units at a price ... proceeds of approximately $10.4 million. Each unit consists of ... overallotment purchase right to purchase 0.50 of a share ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Madison, Wis. -- Implementation of RFID must be done ... technology offers are to be truly realized, attendees at Friday's ... from Patrick Sweeney, CEO of Virginia-based ODIN Technologies ... address at the lab's open house - an event that ...
... pulling all-nighters, but it happens every year twice, in fact, ... night was no exception. , ,After four months of interviewing ... morning to turn the raw ingredients of the selected companies into ... investors and business development execs who come to the event each ...
... BioSurfaces, Inc., of Madison has been licensed to ... and labeling agents, GenTel announced on Tuesday. , ,GenTel ... reagents of Kreatech Biotechnology BV of Amsterdam, ... The kits are validated for use on GenTel's PATH ...
Cached Biology Technology:RFID expert says piecemeal approach won't work 2RFID expert says piecemeal approach won't work 3RFID expert says piecemeal approach won't work 4DEMOfall - A return to simplicity 2DEMOfall - A return to simplicity 3
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... carry out scientifically valid virtual experiments. The method yields ... according to research from the University of Gothenburg, Sweden. ... students from the Swedish town of Lysekil for one ... I2I, Inquiry to Insight., Using scientific data provided by ...
... such as industrial by-products to poisons that occur naturally, a ... every level of toxic material ingested, there is some level ... death. Biosensors have long been used to safeguard ... ancients acted as early versions of biosensors, determining if a ...
... Washington University School of Medicine in St. Louis, will lead ... diagnose, treat and prevent a critical global health problem: malnutrition ... $8.3 million grant from the Bill & Melinda Gates Foundation. ... the trillions of friendly microbes that live in the intestine, ...
Cached Biology News:Real science in virtual school labs 2Dip chip technology tests toxicity on the go 2Dip chip technology tests toxicity on the go 3Washington University receives $8 million to lead international childhood malnutrition effort 2Washington University receives $8 million to lead international childhood malnutrition effort 3Washington University receives $8 million to lead international childhood malnutrition effort 4
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: